MiR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis
McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, Selby PJ, Banks RE, Harris AL (2013)
Publication Type: Journal article
Publication year: 2013
Journal
Book Volume: 108
Pages Range: 1133-1142
Journal Issue: 5
DOI: 10.1038/bjc.2013.56
Abstract
Background: Clear cell renal cancer frequently harbours von Hippel-Lindau (VHL) gene mutations, leading to stabilisation of the hypoxia-inducible factors (HIFs) and expression of their target genes. We investigated HIF-1 and HIF-2 in the regulation of microRNA-210 (miR-210), and its clinical relevance in renal tumours. Methods: RCC4 and 786-O renal cancer cell lines transfected with either an empty vector or functional VHL and incubated in normoxia or hypoxia were examined for miR-210 expression. Hypoxia-inducible factor siRNAs were used to examine their regulation of miR-210. Seventy-one clear cell renal tumours were sequenced for VHL mutations. Expression of miR-210, VHL, CA9, ISCU and Ki-67 were determined by immunohistochemistry and qRT-PCR.Results:In addition to HIF-1 regulating miR-210 in renal cancer, HIF-2 can regulate this microRNA in the absence of HIF-1. MicroRNA-210 is upregulated in renal cancer compared with normal renal cortex tissue. MicroRNA-210 correlates negatively with its gene target ISCU at the protein and mRNA level. MicroRNA-210 correlated with positive outcome variables and negatively with Ki-67. Conclusion: We provide further evidence of miR-210 activity in vivo, and show that high miR-210 expression is associated with better clinico-pathological prognostic factors. © 2013 Cancer Research UK. All rights reserved.
Involved external institutions
St James's University Hospital
United Kingdom (GB)
University of Oxford
United Kingdom (GB)
Wellcome Centre for Human Genetics
United Kingdom (GB)
United Kingdom (GB)
University of Oxford
United Kingdom (GB)
Wellcome Centre for Human Genetics
United Kingdom (GB)
How to cite
APA:
McCormick, R.I., Blick, C., Ragoussis, J., Schoedel, J., Mole, D.R., Young, A.C.,... Harris, A.L. (2013). MiR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. British Journal of Cancer, 108(5), 1133-1142. https://doi.org/10.1038/bjc.2013.56
MLA:
McCormick, R. I., et al. "MiR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis." British Journal of Cancer 108.5 (2013): 1133-1142.
BibTeX: Download